Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Products Biosimilars'

Products Biosimilars published presentations and documents on DocSlides.

ASBM Biosimilars US Prescribers and Biosimilars Naming

ASBM Biosimilars US Prescribers and Biosimilars Naming

  • min-jolicoeur
  • 0 Slides

Kevin Olson, CEO. Industry Standard Research. Kev...

Biosimilars & EU regulation

Biosimilars & EU regulation

  • karlyn-bohler
  • 0 Slides

Alice DOMINIQUE - M2 AREIPS. 1. Content. 2. Defin...

Building a Biosimilars Pathway in the U.S.

Building a Biosimilars Pathway in the U.S.

  • attentionallianz
  • 24 Slides

Richard . Dolinar. , MD. Endocrinologist, Chairman...

Latin American Biologics/Biosimilars Conference

Latin American Biologics/Biosimilars Conference

  • giovanna-bartolotta
  • 13 Slides

Presented by . the Alliance for Safe Bioloigic . ...

Biosimilars

Biosimilars

  • lindy-dunigan
  • 22 Slides

Knowledge Connect Slide Resource. This slide dec...

ASBM Biosimilars

ASBM Biosimilars

  • phoebe-click
  • 38 Slides

US Prescribers and Biosimilars Naming. Kevin Olso...

Biosimilars in RA: A Blessing or a Curse?

Biosimilars in RA: A Blessing or a Curse?

  • conchita-marotz
  • 0 Slides

Introduction/Overview . What Is a Biosimilar?. Di...

US Regulatory Pathway For Biosimilars

US Regulatory Pathway For Biosimilars

  • cheryl-pisano
  • 0 Slides

Practical Legal/Regulatory Considerations Arising...

Biosimilars in the Real World

Biosimilars in the Real World

  • liane-varnes
  • 0 Slides

Introduction/Overview . PLANETRA Extension Study:...

Applying Biosimilars in Hematologic Cancers

Applying Biosimilars in Hematologic Cancers

  • conchita-marotz
  • 0 Slides

This program will include a discussion of off-lab...

Biosimilars are effective and safe and should immediately replace innovator molecules in the NHS

Biosimilars are effective and safe and should immediately replace innovator molecules in the NHS

  • myesha-ticknor
  • 0 Slides

Dr Chris Deighton. Consultant Rheumatologist . Co...

Application of Biosimilars in RA IN Clinical Practice:

Application of Biosimilars in RA IN Clinical Practice:

  • conchita-marotz
  • 0 Slides

Key Issues and Challenges.  . Introduction. Diff...

Biosimilars in emerging markets- regulatory and Commercial considerations

Biosimilars in emerging markets- regulatory and Commercial considerations

  • jane-oiler
  • 0 Slides

OMIC Group. Biosimilars 2104. Hyderabad. India. 2...

Synergy Satellite Event - Biosimilars in colorectal cancer

Synergy Satellite Event - Biosimilars in colorectal cancer

  • mia
  • 16 Slides

– what's your gut feeling?. 25th Anniversary EAH...

  What is the value of Real-World Evidence for Biosimilars?

  What is the value of Real-World Evidence for Biosimilars?

  • bitsy
  • 82 Slides

Disclaimer. This panel is moderated by Dr. Delphin...

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

  • calandra-battersby
  • 0 Slides

OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...

Biological Products: concepts, naming,

Biological Products: concepts, naming,

  • faustina-dinatale
  • 0 Slides

interchangeability,extrapolation. and safety. Dr...

About OMICS Group OMICS Group International is an amalgamation of 

About OMICS Group OMICS Group International is an amalgamation of 

  • sherrill-nordquist
  • 0 Slides

Open Access publications.  and worldwide interna...

Biosimilars in the united states – Update on FDA Impleme

Biosimilars in the united states – Update on FDA Impleme

  • test
  • 37 Slides

James C. Shehan. Hyman, Phelps & McNamara, P....

PhAMA Position on Biosimilar Medicines

PhAMA Position on Biosimilar Medicines

  • celsa-spraggs
  • 0 Slides

Ms. Leah Goodman. Contents. Key Messages. An Over...

A QUM partnership approach to regulating

A QUM partnership approach to regulating

  • liane-varnes
  • 18 Slides

biosimilars. in Australia. David Lim, Evan Siege...

Distinguishable INNs: A Global Solution

Distinguishable INNs: A Global Solution

  • trish-goza
  • 23 Slides

Richard . Dolinar. , MD. Chairman, Alliance for S...

Acceptable changes in quality attributes of glycosylated bi

Acceptable changes in quality attributes of glycosylated bi

  • debby-jeon
  • 19 Slides

Schiestl M, Stangler T, Torella C, et al. . Nat B...

Understanding Biologics Biologics and Biosimilars

Understanding Biologics Biologics and Biosimilars

  • calandra-battersby
  • 0 Slides

Animation: What Are Biologics?. Production of Bio...

United Spinal Association

United Spinal Association

  • alida-meadow
  • 0 Slides

August, 2014. Biologics & Biosimilars: . An O...

Bio similars A Presentation

Bio similars A Presentation

  • kittie-lecroy
  • 0 Slides

By. ANSHUL . SHARMA. Graduate Research Scholar. D...

Latin American Physician Perspectives on Biosimilars

Latin American Physician Perspectives on Biosimilars

  • celsa-spraggs
  • 0 Slides

Presented at the . Latin American Biologics/Biosi...

CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS

CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS

  • iamamercy
  • 26 Slides

Dr.G.Hima. . Bindu. ...

Budget impact and cost-effectiveness of oncology

Budget impact and cost-effectiveness of oncology

  • roxanne
  • 14 Slides

biosimilars. Prof. dr. Steven Simoens. Health econ...

1 Immunogenicity The key safety issue for biosimilars

1 Immunogenicity The key safety issue for biosimilars

  • gelbero
  • 29 Slides

Prof. Ibrahim A. . Alsarra. Professor . of . Phar...

Category 1: Defining Terms

Category 1: Defining Terms

  • jasmine
  • 76 Slides

Clue: . A biologic product with no clinically mean...

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

  • stefany-barnette
  • 0 Slides

OMIC Group Biosimilars 2014. Hyderabad India. 27-...

Roche Position

Roche Position

  • faustina-dinatale
  • 100 Slides

1 1 on Similar Biotherapeutic Products – B...

Phil Johnson MS

Phil Johnson MS

  • stefany-barnette
  • 56 Slides

RPh. Safe School Meds, Principle Partner. Moffitt...

Faculty Leonard H. Calabrese, DO

Faculty Leonard H. Calabrese, DO

  • trish-goza
  • 0 Slides

Professor of Medicine. Cleveland Clinic Lerner Co...

Biosimilars Guideline – a Summary of the Industry Comments

Biosimilars Guideline – a Summary of the Industry Comments

  • marina-yarberry
  • 0 Slides

M Bredenhann | Nycomed | 19.11.10. BIOSIMILAR...

Phil Johnson MS RPh Safe School Meds, Principle Partner

Phil Johnson MS RPh Safe School Meds, Principle Partner

  • yoshiko-marsland
  • 0 Slides

Moffitt Cancer Center, Director of Pharmacy (Reti...

INSIGHTS INTO THE MARKET

INSIGHTS INTO THE MARKET

  • summer
  • 20 Slides

FOR INFLIXIMABTable of ContentsThe Evolving Landsc...

Biosimilars: Additional Questions and Answers Regarding Implementatio

Biosimilars: Additional Questions and Answers Regarding Implementatio

  • mitsue-stanley
  • 100 Slides

&#x/Att;¬he; [/; ott;&#xom ];&#x/BBo...

Biosimilars: Questions and Answers Regarding Implementation of the Bi

Biosimilars: Questions and Answers Regarding Implementation of the Bi

  • danika-pritchard
  • 100 Slides

&#x/Att;¬he; [/; ott;&#xom ];&#x/BBo...

Copyright © 2024 DocSlides. All Rights Reserved